Windgap Medical, Inc., a Watertown, Mass.-based pharmaceutical company, received a strategic investment of undisclosed amount.
The round was led by Shepherd Kaplan Krochuck, with participation from Molex Ventures, a subsidiary of Koch Industries.
Led by Chris Stepanian, CEO and co-founder, Windgap Medical is a pharmaceutical company focused on developing patient solutions utilizing its patented wet/dry drug delivery platform. Its first product is for the administration of epinephrine for anaphylaxis with additional products under development in a number of additional markets.
The company’s products have not been reviewed by the FDA but it intends to seek approval, first, for its epinephrine product for anaphylaxis.